The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Immune Responses to COVID-19 Vaccination in Lymphoma Patients
Official Title: PROSECO - A UK Multicentre Prospective Observational Study Evaluating COVID-19 Vaccine Immune Responses in Lymphoid Cancer
Study ID: NCT04858568
Brief Summary: This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in vaccinated individuals. To do this, we will collect peripheral blood from patients with lymphoid cancers before and after their COVID-19 vaccination. The blood will be explored in the laboratory for antibodies to SARS-CoV-2 and T-cell responses to the spike protein. Detailed clinical information will also be collated on about their cancer and treatment.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Bedfordshire Hospitals NHS Foundation Trust, Bedford, Bedfordshire, United Kingdom
Portsmouth Hospitals University NHS Trust, Portsmouth, Hampshire, United Kingdom
University Hospital Southampton NHS Foundation Trust, Southampton, Hampshire, United Kingdom
Wye Valley NHS Trust, Hereford, Herefordshire, United Kingdom
University Hospitals of Leicester NHS Trust, Leicester, Leicestershire, United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, Norfolk, United Kingdom
Nottingham University Hospitals NHS Trust, Nottingham, Nottinghamshire, United Kingdom
Oxford University Hospitals NHS Foundation Trust, Oxford, Oxfordshire, United Kingdom
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne, Tyne And Wear, United Kingdom